Wegovy for Cardiovascular Risk Reduction - Part 2

In part one we looked at the staggering conflicts of interest and issues with the efficacy in the Semaglutide 2.4 (Wegovy) cardiovascular trial (Semaglutide and Cardiovascular Outcomes in Ob*sity* without Diabetes DOI: 10.1056/NEJMoa2307563) especially as compared to the deeply misleading claims in Novo Nordisk’s “company announcement” publicity stunt prior to publication.Today we’re going to dig deeper into the data, what there is of it, anyway. Get full access to Weight and Healthcare at weightandhealthcare.substack.com/subscribe